Page last updated: 2024-10-26

dipyridamole and Cerebral Arterial Diseases

dipyridamole has been researched along with Cerebral Arterial Diseases in 1 studies

Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.

Cerebral Arterial Diseases: Pathological conditions of intracranial ARTERIES supplying the CEREBRUM. These diseases often are due to abnormalities or pathological processes in the ANTERIOR CEREBRAL ARTERY; MIDDLE CEREBRAL ARTERY; and POSTERIOR CEREBRAL ARTERY.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gautier, JC1
Derouesne, C1
Held, T1
Lhermitte, F1

Other Studies

1 other study available for dipyridamole and Cerebral Arterial Diseases

ArticleYear
[Experimental blood platelet thrombosis in cerebral arteries. Effects of dipyridamole, ergot derivatives and antiserotonin agents].
    La Presse medicale, 1970, Oct-03, Volume: 78, Issue:41

    Topics: Animals; Blood Platelets; Cerebral Arterial Diseases; Cerebral Arteries; Cerebrovascular Circulation

1970